CA2326053A1 - Use of scatter factor to enhance angiogenesis - Google Patents

Use of scatter factor to enhance angiogenesis Download PDF

Info

Publication number
CA2326053A1
CA2326053A1 CA002326053A CA2326053A CA2326053A1 CA 2326053 A1 CA2326053 A1 CA 2326053A1 CA 002326053 A CA002326053 A CA 002326053A CA 2326053 A CA2326053 A CA 2326053A CA 2326053 A1 CA2326053 A1 CA 2326053A1
Authority
CA
Canada
Prior art keywords
scatter factor
tissue
ischemia
nucleic acid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002326053A
Other languages
English (en)
French (fr)
Inventor
Itzhak D. Goldberg
Eliot M. Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Long Island Jewish Medical Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2326053A1 publication Critical patent/CA2326053A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002326053A 1998-03-26 1999-03-26 Use of scatter factor to enhance angiogenesis Abandoned CA2326053A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4881398A 1998-03-26 1998-03-26
US09/048,813 1998-03-26
PCT/US1999/006452 WO1999048537A1 (en) 1998-03-26 1999-03-26 Use of scatter factor to enhance angiogenesis

Publications (1)

Publication Number Publication Date
CA2326053A1 true CA2326053A1 (en) 1999-09-30

Family

ID=21956589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002326053A Abandoned CA2326053A1 (en) 1998-03-26 1999-03-26 Use of scatter factor to enhance angiogenesis

Country Status (6)

Country Link
EP (1) EP1066061A4 (es)
JP (1) JP2002507584A (es)
AU (1) AU3202999A (es)
CA (1) CA2326053A1 (es)
MX (1) MXPA00009440A (es)
WO (1) WO1999048537A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1114862A3 (de) * 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
EP1176200A3 (de) * 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
WO2002089854A1 (fr) * 2001-05-09 2002-11-14 Anges Mg, Inc. Transfert de genes et facteur angiogenique pour maladie de la peau
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
FI20065514A0 (fi) * 2006-08-16 2006-08-16 Licentia Oy Aktivoidut fibroblastit kudosvaurioiden hoitamiseksi

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
ES2240999T3 (es) * 1995-08-29 2005-10-16 Anges Mg, Inc. Medicamento que contiene un gen del hgf.
WO1997012629A1 (en) * 1995-10-05 1997-04-10 Genentech, Inc. Improved angiogenesis using hepatocyte growth factor

Also Published As

Publication number Publication date
MXPA00009440A (es) 2003-04-22
EP1066061A4 (en) 2003-01-08
AU3202999A (en) 1999-10-18
JP2002507584A (ja) 2002-03-12
EP1066061A1 (en) 2001-01-10
WO1999048537A1 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
Takeshita et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia
US6479654B1 (en) Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF
AU666142B2 (en) Viral recombinant vectors for expression in muscle cells
US6685934B1 (en) Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF)
EP2162534A1 (en) Cd34 stem cell-related methods and compositions
US6498144B1 (en) Use of scatter factor to enhance angiogenesis
JP3877148B2 (ja) 糖尿病性虚血性疾患遺伝子治療
EP1370299B1 (en) Nucleic acid constructs expressing vegf and hgf, cells transformed therewith and their use for inducing liver regeneration and alleviation of portal hypertension
US7709450B2 (en) Stimulation of vascularization with VEGF-B-186
CA2326053A1 (en) Use of scatter factor to enhance angiogenesis
KR20190015153A (ko) 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학적 조성물
US20030228283A1 (en) Preventing secondary lymphedema with VEGF-D DNA
US6793918B2 (en) In vivo stimulation of angiogenic activity
US6743623B2 (en) Viral recombinant vectors for expression in muscle cells
US6099831A (en) Viral recombinant vectors for expression in muscle cells
US20030148952A1 (en) Methods and materials for the recruitment of endothelial cells
US7476654B2 (en) Method for modulating, regulating and/or stabilizing angiogenesis
Vranckx et al. 15 Gene Transfer of Growth Factors for Wound Repair
AU2002326311A1 (en) Stimulation of vascularization with VEGF-B
CA2897188A1 (en) Cd34 stem cell-related methods and compositions
AU2004200697A1 (en) Variants of the Angiogenic Factor Vascular Endothelial Cell Growth Factor: VEGF

Legal Events

Date Code Title Description
FZDC Correction of dead application (reinstatement)
FZDE Dead